1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Anxo Pharmaceutical Co., Ltd.

Anxo Pharmaceutical Co., Ltd.

TTPEX:6677
18.80
TWD
-0.15
(-0.79%)
927.45MMarket Cap
Anxo Pharmaceutical Co., Ltd.
TPEX:6677
(Taipei Exchange)

Recent

price

18.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
22.95
18.74
14.66
15.45
18.26
18.87
17.39
16.5
17.99
18.49
16.07
15.09
- -
Revenue per Share
- -
0.94
-0.71
-0.45
-0.63
0.62
0.52
0.63
0.39
-0.26
0.43
-1.03
-0.61
- -
Basic EPS, GAAP
- -
-1.22
-8.39
-8.18
-0.6
-0.58
0.76
0.88
0.89
1.13
-1.19
0.92
0.11
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.23
- -
- -
- -
0.4
- -
- -
Dividend per Share
1.62
11.22
10.62
10.2
11.65
12.33
12.84
14.28
14.68
14.52
19.57
18.32
17.72
17.6
Book Value per Share
-0.83
9.16
8.22
7.82
9.83
10.89
11.69
13.44
13.86
13.68
18.85
17.49
16.92
16.83
Tangible Book Value per Share
47
28
34
44
46
47
47
50
50
48
51
56
56
56
Basic Weighted Avg Shares
- -
643
631
642
705
850
878
866
824
866
940
895
843
- -
Sales/Revenue/Turnover
- -
4.74
-3.42
-3.26
-3.13
6.24
5.17
6.6
4.84
0.72
5.65
-6.3
-5.09
- -
Operating Margin (%)
- -
33
40
51
72
75
86
81
74
74
75
77
76
- -
Depreciation Expense
- -
26
-24
-20
-29
29
24
31
19
-13
22
-57
-34
- -
Net Income, GAAP
- -
36
- -
- -
- -
24.42
25.96
21.07
18.85
- -
20.38
- -
- -
- -
Effective Tax Rate (%)
- -
4.1
-3.78
-3.07
-4.11
3.37
2.75
3.63
2.33
-1.45
2.33
-6.39
-4.05
- -
Profit Margin (%)
-203
334
87
-51
96
97
114
239
232
216
492
376
308
261
Working Capital
357
446
545
679
729
660
670
625
594
562
500
449
395
369
LT Debt
205
653
618
592
670
703
689
811
832
830
1,203
1,139
1,108
1,101
Total Equity
- -
1.99
- -
- -
- -
2.48
2.05
2.7
1.9
- -
2.28
- -
- -
- -
Return on Invested Capital (%)
- -
3.27
- -
- -
- -
2.5
2.38
2.12
1.7
- -
1.47
- -
- -
- -
Return on Capital (%)
- -
8.81
-4.69
-4.06
-5.69
5.13
4.12
4.79
2.66
-1.72
2.41
-5.42
-3.39
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
295
340
372
LT Borrowings
413
389
367
LT Finance Leases
11
6
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
56
56
56
Market Capitalization
967
1,050
927

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
824
848
846
Cash, Cash Equivalents & STI
340
387
335
Accounts Receivable, Net
175
162
195
Inventories
264
254
260
Total Current Liabilities
491
539
585
Payables & Accruals
- -
- -
- -
ST Debt
295
340
372
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.89%
7.84%
-2.74%
Free Cash Flow
-73.3%
-92%
-88.45%
Net Income, GAAP
-103.52%
-176.03%
-40.34%
Sales/Revenue/Turnover
3.23%
-0.36%
-5.81%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
895
2025
- -
- -
843
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.03
2025
- -
- -
-0.61
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.4
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Anxo Pharmaceutical Co., Ltd. (6677.TWO) develops, manufactures, and markets specialty generic prescription and over-the-counter (OTC) pharmaceutical products targeting therapeutic areas including cardiovascular and metabolism, central nervous system (CNS), diabetic, gastroenterology, respiratory, anti-infection, dermatology, ophthalmology/otology, nephrology, urology, and orthopedics; offerings encompass oral medications, injections, dermatology/external use preparations, and OTC drugs, with a focus on advanced dosage forms such as extended-release, controlled-release, and specialty generics that represent many first-to-market approvals in Taiwan. The company, founded in 2003 and headquartered in Taipei, Taiwan, with an R&D center in Hsinchu, operates primarily in Taiwan while pursuing international partnerships across Asia, Europe, and America through sales authorization, contract manufacturing (CMO), contract development (CDMO), technology transfer, and co-development models. Anxo leverages proprietary technology platforms for specialty dosage forms, formulation/process development, and analytical methods to enhance patient compliance, reduce side effects, and support 505(b)(2) products. In recent developments, Anxo partnered with Sunny Pharmtech Inc. in 2024 to co-develop high-margin cardiovascular drugs, including a rare disease softgel formulation (TFM-SC) targeting the U.S. market with planned regulatory filing by 2027, building on prior pulmonary fibrosis collaboration; the company also expanded ties with a U.S. entity for additional products like TMN-T (oncology) and MSL-T (ulcerative colitis). Further, Anxo entered a strategic collaboration with EUSOL Biotech Co., Ltd. to develop novel oral anticoagulants and niche generic drugs, capitalizing on post-patent opportunities in Taiwan; in September 2025, it filed a U.S. FDA Phase I IND for schizophrenia treatment AX251. These initiatives underscore Anxo's shift toward global expansion, CMO/CDMO growth, and innovative pipelines amid evolving international pharmaceutical dynamics.